Literature DB >> 25525571

Epithelial ovarian cancer: An overview.

Arpita Desai1, Jingyao Xu2, Kartik Aysola2, Yunlong Qin2, Chika Okoli2, Ravipati Hariprasad3, Ugorji Chinemerem3, Candace Gates2, Avinash Reddy2, Omar Danner4, Geary Franklin2, Anachebe Ngozi2, Guilherme Cantuaria5, Karan Singh6, William Grizzle6, Charles Landen6, Edward E Partridge6, Valerie Montgomery Rice2, E Shyam P Reddy2, Veena N Rao2.   

Abstract

Ovarian cancer is the second most common gynecological cancer and the leading cause of death in the United States. In this article we review the diagnosis and current management of epithelial ovarian cancer which accounts for over 95 percent of the ovarian malignancies. We will present various theories about the potential origin of ovarian malignancies. We will discuss the genetic anomalies and syndromes that may cause ovarian cancers with emphasis on Breast cancer type 1/2 mutations. The pathology and pathogenesis of ovarian carcinoma will also be presented. Lastly, we provide a comprehensive overview of treatment strategies and staging of ovarian cancer, conclusions and future directions.

Entities:  

Keywords:  Breast cancer type 1; Chemotherapy; Epithelial ovarian cancer

Year:  2014        PMID： 25525571      PMCID： PMC4267287          DOI： 10.5528/wjtm.v3.i1.1

Source DB:  PubMed          Journal:  World J Transl Med        ISSN： 2220-6132


  58 in total

Review 1.  Pathology of borderline (low malignant potential) ovarian tumours.

Authors:  Jeffrey D Seidman; Brigitte M Ronnett; Robert J Kurman
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2002-08       Impact factor: 5.237

2.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

Review 3.  Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor.

Authors:  N Katsumata
Journal:  Ann Oncol       Date:  2011-12       Impact factor: 32.976

4.  Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.

Authors:  Dorina M van der Kolk; Geertruida H de Bock; Beike K Leegte; Michael Schaapveld; Marian J E Mourits; Jakob de Vries; Annemieke H van der Hout; Jan C Oosterwijk
Journal:  Breast Cancer Res Treat       Date:  2010-03-04       Impact factor: 4.872

5.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

6.  Variation in cancer risks, by mutation position, in BRCA2 mutation carriers.

Authors:  D Thompson; D Easton
Journal:  Am J Hum Genet       Date:  2001-01-19       Impact factor: 11.025

7.  The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma.

Authors:  H M Goodman; B L Harlow; E E Sheets; M G Muto; S Brooks; M Steller; R C Knapp; R S Berkowitz
Journal:  Gynecol Oncol       Date:  1992-09       Impact factor: 5.482

8.  Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Authors:  Usha Menon; Aleksandra Gentry-Maharaj; Rachel Hallett; Andy Ryan; Matthew Burnell; Aarti Sharma; Sara Lewis; Susan Davies; Susan Philpott; Alberto Lopes; Keith Godfrey; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Ian Scott; Tim Mould; Robert Woolas; John Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Alistair McGuire; Stuart Campbell; Lesley Fallowfield; Naveena Singh; Anne Dawnay; Steven J Skates; Mahesh Parmar; Ian Jacobs
Journal:  Lancet Oncol       Date:  2009-03-11       Impact factor: 41.316

9.  When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes.

Authors:  Linda R Duska; Leslie Garrett; Melissa Henretta; J Stuart Ferriss; Lisa Lee; Neil Horowitz
Journal:  Gynecol Oncol       Date:  2010-03       Impact factor: 5.482

10.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

Authors:  Paul A Vasey; Gordon C Jayson; Alan Gordon; Hani Gabra; Rob Coleman; Ronnie Atkinson; David Parkin; James Paul; Andrea Hay; Stan B Kaye
Journal:  J Natl Cancer Inst       Date:  2004-11-17       Impact factor: 13.506
View more
  46 in total

1.  Retraction note to: KDM3A confers metastasis and chemoresistance in epithelial ovarian cancer.

Authors: 
Journal:  J Mol Histol       Date:  2015-12       Impact factor: 2.611

2.  Survivin siRNA increases sensitivity of primary cultures of ovarian cancer cells to paclitaxel.

Authors:  R Kar; J K Palanichamy; A Banerjee; P Chattopadhyay; S K Jain; N Singh
Journal:  Clin Transl Oncol       Date:  2015-06-02       Impact factor: 3.405

3.  Long non-coding RNA LINC00504 regulates the Warburg effect in ovarian cancer through inhibition of miR-1244.

Authors:  Ya Liu; Xiaocui He; Yuli Chen; Dan Cao
Journal:  Mol Cell Biochem       Date:  2019-11-05       Impact factor: 3.396

4.  Akt2/ZEB2 may be a biomarker for exfoliant cells in ascitic fluid in advanced grades of serous ovarian carcinoma.

Authors:  Changmei Liu; Fangmei Yang
Journal:  Tumour Biol       Date:  2015-04-19

Review 5.  Current update on the molecular genetics and management of hereditary ovarian cancers: a primer for radiologists.

Authors:  Malak Itani; Neeraj Lalwani; Dhakshinamoorthy Ganeshan; Maria Zulfiqar; Cary Siegel
Journal:  Abdom Radiol (NY)       Date:  2021-04-13

Review 6.  Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.

Authors:  Aashna Patel; Roshni Kalachand; Steven Busschots; Ben Doherty; Evangelos Kapros; Denise Lawlor; Neville Hall; Britta K Stordal
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

7.  Anticancer activity of NOB1-targeted shRNA combination with TRAIL in epithelial ovarian cancer cells.

Authors:  Yang Lin; Tianmin Xu; Hong Teng; Manhua Cui
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.

Authors:  Xianzhe Liu; Yan Gao; Jacson Shen; Wen Yang; Edwin Choy; Henry Mankin; Francis J Hornicek; Zhenfeng Duan
Journal:  Mol Cancer Ther       Date:  2016-05-20       Impact factor: 6.261

9.  Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites.

Authors:  A Desai; J Xu; K Aysola; O Akinbobuyi; M White; V E Reddy; J Okoli; C Clark; E E Partridge; Ed Childs; D J Beech; M V Rice; Esp Reddy; V N Rao
Journal:  J Gynecol Res       Date:  2015-04-24

10.  Potential role of HGF-PARP-1 signaling in invasion of ovarian cancer cells.

Authors:  Wei Wei; Shuqing Lv; Cancan Zhang; Yongjie Tian
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.